Buscar
Immunocore Holdings PLC
IMCRAñadir a la lista de seguimiento
33.810USD
-0.060-0.18%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.72BCap. mercado
PérdidaP/E TTM
Más Datos de Immunocore Holdings PLC Compañía
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Información de Immunocore Holdings PLC
Símbolo de cotizaciónIMCR
Nombre de la empresaImmunocore Holdings PLC
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoJallal (Bahija)
Número de empleados493
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 05
Dirección92 Park Drive Milton Park
CiudadABINGDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalOX14 4RY
Teléfono441235438600
Sitio Webhttps://www.immunocore.com/
Símbolo de cotizaciónIMCR
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoJallal (Bahija)
Ejecutivos de Immunocore Holdings PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
12.34K
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
12.34K
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Immunocore Holdings PLC?
Los cinco principales accionistas de Immunocore Holdings PLC son: Prof. John Bell
¿Cuántas instituciones poseen acciones de Immunocore Holdings PLC (IMCR)?
A fecha de 2026Q1, 320 instituciones poseen acciones de Immunocore Holdings PLC, con un valor de mercado combinado de aproximadamente 49.60M, lo que representa el 97.50% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -9831616.00.